Ecor1 Capital, Llc Purchases 21,021 Shares of Zymeworks Inc. (NYSE:ZYME) Stock

Zymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc purchased 21,021 shares of Zymeworks stock in a transaction on Wednesday, January 8th. The stock was purchased at an average price of $14.07 per share, for a total transaction of $295,765.47. Following the completion of the transaction, the director now owns 15,206,980 shares of the company's stock, valued at approximately $213,962,208.60. This represents a 0.14 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Friday, January 10th, Ecor1 Capital, Llc bought 204,098 shares of Zymeworks stock. The stock was purchased at an average price of $13.13 per share, with a total value of $2,679,806.74.
• On Thursday, January 2nd, Ecor1 Capital, Llc acquired 157,880 shares of Zymeworks stock. The stock was acquired at an average price of $14.78 per share, with a total value of $2,333,466.40.
• On Monday, December 30th, Ecor1 Capital, Llc bought 58,988 shares of Zymeworks stock. The shares were acquired at an average price of $14.47 per share, for a total transaction of $853,556.36.
• On Tuesday, December 24th, Ecor1 Capital, Llc purchased 11,958 shares of Zymeworks stock. The shares were bought at an average price of $14.12 per share, for a total transaction of $168,846.96.
• On Thursday, December 26th, Ecor1 Capital, Llc purchased 16,692 shares of Zymeworks stock. The stock was bought at an average cost of $14.38 per share, with a total value of $240,030.96.

Zymeworks Stock Down 6.4 %

Zymeworks stock traded down $0.91 during midday trading on Friday, hitting $13.22. 798,973 shares of the stock were exchanged, compared to its average volume of 594,729. Zymeworks Inc. has a 52 week low of $7.97 and a 52 week high of $17.70. The stock has a market capitalization of $910.57 million, a PE ratio of -8.81 and a beta of 1.10. The company has a fifty day simple moving average of $14.48 and a two-hundred day simple moving average of $12.39.

Zymeworks (NYSE:ZYME - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.01. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The company had revenue of $16.00 million during the quarter, compared to analyst estimates of $17.90 million. During the same quarter in the previous year, the business earned ($0.41) EPS. The firm's revenue was down 3.1% on a year-over-year basis. As a group, equities research analysts anticipate that Zymeworks Inc. will post -1.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Barclays PLC increased its position in shares of Zymeworks by 476.3% during the third quarter. Barclays PLC now owns 154,384 shares of the company's stock worth $1,937,000 after acquiring an additional 127,595 shares in the last quarter. Jane Street Group LLC raised its stake in shares of Zymeworks by 27.3% in the 3rd quarter. Jane Street Group LLC now owns 80,326 shares of the company's stock valued at $1,008,000 after purchasing an additional 17,205 shares during the period. State Street Corp lifted its holdings in shares of Zymeworks by 6.1% in the third quarter. State Street Corp now owns 1,171,777 shares of the company's stock valued at $14,706,000 after purchasing an additional 67,401 shares in the last quarter. Stifel Financial Corp boosted its position in shares of Zymeworks by 2.1% during the third quarter. Stifel Financial Corp now owns 73,654 shares of the company's stock worth $924,000 after buying an additional 1,540 shares during the period. Finally, Vestal Point Capital LP grew its holdings in shares of Zymeworks by 39.8% during the third quarter. Vestal Point Capital LP now owns 615,000 shares of the company's stock worth $7,718,000 after buying an additional 175,000 shares in the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ZYME shares. Stifel Nicolaus increased their price objective on Zymeworks from $21.00 to $28.00 and gave the company a "buy" rating in a research report on Monday, October 28th. HC Wainwright reiterated a "neutral" rating and issued a $12.00 price objective on shares of Zymeworks in a research report on Friday, November 22nd. JPMorgan Chase & Co. upgraded shares of Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 target price on the stock in a research report on Monday, December 16th. Wells Fargo & Company raised their target price on shares of Zymeworks from $12.00 to $14.00 and gave the company an "equal weight" rating in a research note on Thursday, December 19th. Finally, Citigroup boosted their price target on shares of Zymeworks from $16.00 to $18.00 and gave the stock a "buy" rating in a research note on Monday, November 4th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $19.17.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.